Blood pressure, mealtime insulin, and MASLD: 3 findings to discuss this week
A July 29 AHA analysis and two July 28–31 studies show why patients should review blood-pressure readings, insulin timing, and liver-related cardiovascular risk with their clinicians—not act on a single number.
The most useful message in this week's verified evidence is simple: a blood-pressure reading, an insulin schedule, or a liver-risk marker needs context before it becomes a treatment decision.
Quick view: what deserves attention now
- High blood pressure: A July 29 American Heart Association report describes an analysis suggesting that millions of US adults may be eligible for medication under the 2025 AHA/ACC guideline. This is a reason to review repeated readings and overall risk, not to start a drug based on one number.
- Mealtime insulin: A July 28 survey found that insulin users who reported injecting before meals had better glucose measures than those who injected at other times. It was a cross-sectional Spanish study, so it does not prove that changing timing will improve your numbers.
- MASLD and heart risk: A July 31 analysis found that metabolic dysfunction-associated steatotic liver disease (MASLD) was linked with worse long-term outcomes even when lipoprotein(a), or Lp(a), was not elevated. A liver diagnosis belongs in the cardiovascular-risk conversation too.
1. A single blood-pressure reading is not a prescription
The American Heart Association reported July 29 on a peer-reviewed analysis in the Journal of the American Heart Association. The researchers applied the 2025 AHA/ACC high blood-pressure guideline to National Health and Nutrition Examination Survey data collected from 2009 through 2018. Among an estimated 81 million US adults with high blood pressure and no known cardiovascular disease, 22.8 million, or 28%, appeared eligible for blood-pressure-lowering medication under the guideline. Of that eligible group, 9.7 million were not receiving treatment. 1
Those numbers are a population estimate, not a prescription for a particular reader. The analysis used blood pressure measured at one office visit, while the guideline calls for readings from multiple visits. The researchers also did not randomly assign treatment. That means the study can show how many people might fit the guideline's criteria; it cannot tell you that medication is right for you without confirming your usual blood pressure and other risks. 1
The guideline's decision is more layered than "130/80 means take a pill." For adults ages 30 to 79 without known cardiovascular disease, clinicians use the PREVENT equations to estimate 10-year and 30-year cardiovascular risk. The AHA report says that for some people with readings below 140/90 and no history of heart disease, stroke, chronic kidney disease, or diabetes, lifestyle changes may be enough at first. A lower PREVENT score can also support a lifestyle-first conversation. Those exceptions matter: many readers of this channel have diabetes or kidney disease, which can change the discussion. 1
What to do this week: If your office blood pressure has been high, ask how many readings are needed to confirm the pattern and how your diabetes, kidney function, cholesterol, smoking history, or prior heart event changes your medication threshold. If you already check at home, bring the record rather than a single best-looking number.
2. Insulin timing is worth reviewing, but this study does not create a universal 15-minute rule
A study published online July 28 in Diabetes Therapy surveyed 288 adults in Spain who used multiple daily insulin injections. Nearly three-quarters had type 1 diabetes. In the survey, 83.3% said they injected mealtime insulin before eating, but only 71.2% said they did so at least 15 minutes before a meal. People who reported injecting before meals had a higher rate of HbA1c at or below 7.5% (83.3% versus 62.5%), more time in the target glucose range (74.4% versus 66.3%), and lower mean glucose (144 versus 159 mg/dL). 2
The practical signal is about education and routine. The survey also found that dosing mistakes were common: 38.5% reported underdosing more than five times in the previous month, and 26.7% reported overdosing that often. Smart-pen users reported fewer mild-to-moderate hypoglycemic events, but the study did not find differences in HbA1c or time in range for smart-pen users. 2
There are two important brakes on the headline. First, this was a cross-sectional survey: it measured behavior and glucose outcomes at one point, so it cannot show that injecting earlier caused the better readings. People who inject before meals may differ in education, insulin type, meal planning, access to devices, or other habits. Second, the sample was mostly people with type 1 diabetes in Spain. The result should prompt a medication-timing review, not a US-wide instruction.
Insulin timing also depends on the formulation and the plan your clinician gave you. Do not move an injection earlier, later, or closer to a meal because of a headline. If meals are unpredictable, ask what to do when you cannot eat as planned, what to do after a missed or delayed dose, and which glucose reading or symptom should trigger a call.
What to do this week: Write down one ordinary day's meal times, insulin times, glucose checks, and any low or high readings. Bring that sequence to your diabetes visit and ask whether the timing, dose, insulin-to-carbohydrate ratio, or injection technique needs review.
3. MASLD can raise concern even when Lp(a) is not high
The liver study published July 31 in Metabolism examined data from the Multi-Ethnic Study of Atherosclerosis, a prospective cohort. The researchers used CT-based measures to identify MASLD alongside a cardiometabolic risk factor and excluded people whose alcohol intake exceeded the study's limits. They then compared liver status with blood levels of lipoprotein(a), usually shortened to Lp(a). Lp(a) is an LDL-like particle associated with artery disease, but it is not the same test as ordinary LDL cholesterol. 3
The result looks counterintuitive at first. Median Lp(a) was lower in participants with MASLD than in those without it: 11.9 versus 18.1 mg/dL. Yet among people with low Lp(a) (50 mg/dL or less), those with MASLD had a higher risk of death from any cause than people without MASLD and with low Lp(a): hazard ratio 1.28, with a 95% confidence interval of 1.025 to 1.56. Among people with MASLD and elevated Lp(a), the risk of hard cardiovascular disease was higher than in people without MASLD and with Lp(a) at or below 50 mg/dL: hazard ratio 2.07, with a 95% confidence interval of 1.39 to 3.09. 3
A hazard ratio compares the rate at which an outcome occurred in one group with the rate in a comparison group during follow-up. It is not a percentage-point prediction for one person. A hazard ratio of 1.28 does not mean that 28 out of 100 people will die, and it does not prove that MASLD caused the difference. It describes an association after the researchers adjusted for traditional cardiovascular risk factors.
The patient-facing lesson is stronger than "get one more test." A lower Lp(a) did not cancel the risk associated with MASLD in this analysis. If you have MASLD, your appointment should cover the liver and the conditions that travel with it: blood pressure, diabetes, cholesterol, weight, sleep apnea when relevant, and fibrosis risk. The study was observational and does not set a personal medication threshold or prove that treating Lp(a) will prevent an outcome.
What to do this week: Ask, "How are we assessing my liver-fibrosis risk, and how does my cardiovascular risk fit into that plan?" If your clinician mentions Lp(a), ask what decision the result would change rather than treating the number as a stand-alone verdict.
Four questions for your next appointment
- Blood pressure: Do I need repeated home or office readings, and how do my PREVENT risk and other conditions affect the medication discussion?
- Insulin: For my specific insulin, meals, and activity, what timing is safest and what should I do when a meal is delayed or skipped?
- MASLD: What is my current fibrosis risk, and when should it be reassessed?
- Whole-person plan: Which numbers should we review together—blood pressure, glucose, cholesterol, kidney tests, liver tests, or Lp(a)—instead of interpreting one in isolation?
These updates are useful because they sharpen the questions. They are not reasons to start, stop, or retime a medication without the clinician who knows your medical history.
This article is for appointment preparation and caregiver discussion. It does not replace individualized medical advice.
참고 출처
- 1
- 2
- 3
Chronic Disease Management Brief
Weekly translation of the latest diabetes / cardiovascular / liver disease management guidelines into everyday language
이 콘텐츠는 채널이 자동으로 생성했습니다. 한 문장이면 Neodrop이 당신을 위해 계속 만들어 냅니다.
관련 콘텐츠
- 로그인하면 댓글을 작성할 수 있습니다.